Skip to content

Paracervical Block During II-trimester Abortion

Paracervical Block (PCB) During II-trimester Abortion- A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01617564
Enrollment
112
Registered
2012-06-12
Start date
2012-05-31
Completion date
2015-05-31
Last updated
2015-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Second Trimester Medical Abortion

Keywords

medical abortion, second trimester, para cervical blockage, pain management

Brief summary

Paracervical blockage can reduce severe pain during second trimester induced medical abortion.

Interventions

DRUGbipuvacain

PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).

OTHERNaCl

PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator

Sponsors

Kristina Gemzell Danielsson
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Women who request second trimester medical abortion (13-22 weeks gestation according to ultrasound) * 18 years of age or older * able to understand and communicate in Swedish * able to understand the study related information and willing to give her * informed consent to participation in the study

Exclusion criteria

* Known allergy to bupivakain or related substances

Design outcomes

Primary

MeasureTime frameDescription
Pain scoreat 24 hoursPain indicated on VAS at specific time intervals during the induction to expulsion

Secondary

MeasureTime frameDescription
Efficacyafter 24h from inductionNumber of complete abortions within 24h without the need for surgery
Time to abortionat 24hoursTime from induction (first dose of misoprostol) to expulsion
Number of Participants with Adverse Events as a Measure of Safety and Tolerabilityat 6 to 8 weeksAEs reported during the time period from mifepristone (Day 1)until follow up

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026